节点文献

HIFU联合TACE治疗不能手术切除中晚期肝癌的临床分析

Clinical Analysis of Middle-late Stage Inoperable Hepatocellular Carcinoma Treated with High Intensity Focused Ultrasound Plus Transcatheter Arterial Chemoembolization

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 金成兵朱辉王智彪伍烽陈文直张炼黎克全苏海兵

【Author】 Jin Chengbing,Zhu Hui,Wang Zhibiao,et al Clinical Center of Tumor Therapy,2nd Affiliated Hospital,Chongqing Medical University,Chongqing 400010 China

【机构】 重庆医科大学附属第二医院肿瘤治疗中心

【摘要】 目的探讨高强度聚焦超声(HIFU)联合经导管动脉栓塞治疗(TACE)治疗中晚期肝癌的疗效,并行临床分析。方法随访联合治疗的73例不能手术切除中晚期肝癌和临床分析肝功、门静脉侵犯、肿瘤大小、数目等12个因素。结果总中位生存时间为12个月,1、2、3年生存率依次为49.1%、18.8%、8.4%。单因素分析,年龄、肿瘤大小、肿瘤数目、1997TNM分期、门静脉侵犯有统计学意义(P=0.017、0.000、0.039、0.023、0.02);多因素分析,肿瘤大小有统计学意义(P=0.013)。结论HIFU联合TACE能改善不能手术中晚期肝癌的生存。肿瘤大小是影响预后的独立因素。

【Abstract】 Objective To study the efficacy of high intensity focused ultrasound(HIFU)plus transcatheter arterial chemoembolization(TACE)in the treatment of patients with middle-late stage inoperable hepatocellular carcinoma(HCC)and to analyse clinically.Methods Seventy-three HCC patients(1997 TNM stage III A 25,ⅣA 48)who were treated with HIFU plus TACE were followed up.The clinical varibles of gender,age,AFP level,liver function,tumor location,tumor numbers,tumor size,TNM staging,portal vein invasion,ultrasound pathway of HIFU and TACE times were all analyzed.Results Median survival time was 12 months.Survival rates of 1,2 and 3 year were 49.1%,18.8% and 8.4%,respectively.On univariate analysis,age(P=0.017),tumor size(P=0.000),tumor numbers(P=0.039),1997 TNM staging(P=0.023),and portal vein invasion(P=0.02)were significant predictors.Tumor size was an independent predictor on multivariate analysis(P=0.013).Conclusions HIFU plus TACE may prolong survival of middle-late stage inoperable HCC patients.Tumor size was an important predictor.

【基金】 国家自然科学基金资助项目(No.30171060)
  • 【文献出处】 中国超声医学杂志 ,Chinese Journal of Ultrasound in Medicine , 编辑部邮箱 ,2008年08期
  • 【分类号】R735.7
  • 【被引频次】36
  • 【下载频次】150
节点文献中: 

本文链接的文献网络图示:

本文的引文网络